- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 16:46 | Leadership changes afoot at two CGT biotechs | ||
| 12:46 | Apnimed scouts $160m IPO to back late-stage sleep apnoea pill development | ||
| 11:46 | BioMarin and n-Lorem partner on early research for ReNU syndrome therapy | ||
| 10:46 | argenx signs agreement to buy Forte Biosciences for $2.2bn | ||
| Mo | Outlook Therapeutics wins FDA approval for Lytenava in wet AMD | ||
| Mo | Biointron introduces RushData platform for AI-driven antibody discovery | ||
| Mo | Kenvue's Tylenol with Naproxen gains FDA approval | ||
| Fr | Sanofi abandons eczema drug approval efforts in another blow to OX40 class | ||
| Fr | BeOne to invest $300m in US manufacturing facility expansion | ||
| Fr | FDA grants fast track designation for Lundbeck's Lu AH69593 | ||
| Do | GSK secures first lung cancer approval, validating $10.6bn Nuvalent bet | ||
| Do | Affinia Therapeutics receives FDA orphan drug designation for AFTX-201 | ||
| Do | Evogene and ELEO to develop new oral PCSK9 inhibitors | ||
| Do | Crystalys banks $130m to progress gout drug, plan for commercial readiness | ||
| Mi | US generic tariff reprieve on the rocks as Trump proposes 100% rate in 2028 | ||
| Mi | Kyowa Kirin EMEA's Crysvita approved by EC for infants with XLH | ||
| Mi | Cellares and Papillon partner for PPL-001 manufacturing automation | ||
| 21.07. | Novo sues Lilly after alleged misleading and false advertising campaign | ||
| 21.07. | Novartis Q2 profits recover as revenue mantle passes to newer medicines | ||
| 21.07. | Bristol Myers, NVIDIA join forces to build life science's 'most powerful' AI factory | ||
| 21.07. | EMA's CHMP grants PRIME status to AbelZeta's C-CAR168 | ||
| 21.07. | Halozyme and Incyte sign licence agreement for INCA033989 formulations | ||
| 20.07. | Novartis and Takeda drugs gain rare blood cancer routine use on NHS | ||
| 20.07. | Samsung Biologics to acquire PolyPeptide in $1.81bn cash deal | ||
| 20.07. | UK biotech financing continues recovery trajectory on five-year Q2 high |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.